Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ARCHIVE
ARCHIVE
- Development of Anti-obesity Drug Contrave Suspended in US
June 20, 2011
- Chuikyo to Resume Discussions on Next Round of Drug Pricing Reform on June 22
June 20, 2011
- Agensys, Seattle Genetics to Codevelop ADC ASG-22ME: Astellas
June 20, 2011
- PMDA Accelerating Preparations for Membership in PIC/S
June 20, 2011
- DSP, TRANS GENIC, Univ. of Tokyo Sign Joint Research Agreement for AIM
June 20, 2011
- Concern Growing About Gov't Plan to Revise Patients' Drug Copayments
June 20, 2011
- Fujitsu, Univ. of Tokyo to Jointly Develop Technology for Creating LMW Compounds
June 20, 2011
- Lilly Transfers Evista to Takeda in 7 Asian Markets
June 13, 2011
- Promotion Office Discussing Establishment of “Drug Discovery Support Institute”
June 13, 2011
- Prof. Kadowaki to Collect Evidence under Intensified Therapy Using Incretin-related Drugs
June 13, 2011
- Kyowa Kirin, Ferring to Copromote Desmopressin ODT for Enuresis
June 13, 2011
- Korosho to Make Unapproved Drugs under Development Available for Use
June 13, 2011
- Nippon Shinyaku to Market 3 PH Treatments Mid-decade
June 13, 2011
- Rights to PD Treatment KW-6002 in North America Returned to Kyowa Kirin
June 13, 2011
- Ono, DSP to Codevelop CTS as Additional Indication for Limaprost
June 13, 2011
- Bendamustine to Be Marketed by Eisai in South Korea: SymBio
June 13, 2011
- BMS, Roche to Collaborate in PI/II Trials of Combination Treatment for Melanoma
June 13, 2011
- 9 Companies Inaugurate Japan CSO Association on June 1
June 13, 2011
- Trisenox Launched in South Korea through BL&H: Nippon Shinyaku
June 13, 2011
- Sanofi Pasteur to Develop Single-antigen IPV in Japan
June 13, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…